(Q35807188)

English

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

scientific article published on 23 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer (English)

1 reference

Europe PubMed Central

10 August 2017

Carla S. Fisher

10

object named as

Carla Fisher

1 reference

Europe PubMed Central

10 August 2017

Brian Czerniecki

13

object named as

Brian J Czerniecki

1 reference

Europe PubMed Central

10 August 2017

Elizabeth Fitzpatrick

4

object named as

Elizabeth Fitzpatrick

1 reference

Europe PubMed Central

10 August 2017

Robert E. Roses

11

object named as

Robert E Roses

1 reference

Europe PubMed Central

10 August 2017

author name string

Jashodeep Datta

1

1 reference

Europe PubMed Central

10 August 2017

Erik Berk

2

1 reference

Europe PubMed Central

10 August 2017

Shuwen Xu

3

1 reference

Europe PubMed Central

10 August 2017

Cinthia Rosemblit

5

1 reference

Europe PubMed Central

10 August 2017

Lea Lowenfeld

6

1 reference

Europe PubMed Central

10 August 2017

Noah Goodman

7

1 reference

Europe PubMed Central

10 August 2017

David A Lewis

8

1 reference

Europe PubMed Central

10 August 2017

Paul J Zhang

9

1 reference

Europe PubMed Central

10 August 2017

Angela DeMichele

12

1 reference

Europe PubMed Central

10 August 2017

publication date

23 May 2015

1 reference

Europe PubMed Central

10 August 2017

Breast Cancer Research

1 reference

Europe PubMed Central

10 August 2017

17

1 reference

Europe PubMed Central

10 August 2017

71

1 reference

Europe PubMed Central

10 August 2017

https://scigraph.springernature.com/pub.10.1186/s13058-015-0584-1

0 references

Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Optimizing dendritic cell-based approaches for cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Pathological features and prognosis of different molecular subtypes of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8+T-Cell Function in Melanoma Patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

HER2/neu in the management of invasive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

11 July 2018

Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

25 September 2018

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

25 September 2018

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

25 September 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

25 September 2018

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

25 September 2018

High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488128

25 September 2018

Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy

1 reference

https://api.crossref.org/works/10.1186%2FS13058-015-0584-1

21 January 2018

Detection of low-frequency antigen-specific IL-10-producing CD4(+) T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25997452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25997452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S13058-015-0584-1

1 reference

Europe PubMed Central

10 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35807188&oldid=1998022731"